Person:
DİNÇ, HARİKA ÖYKÜ

Profile Picture
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
HARİKA ÖYKÜ
Last Name
DİNÇ
Name
Email Address
Birth Date

Filters

2020 - 20225
Reset filters

Settings

Subject: COVID-19 ×

Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    PublicationOpen Access
    Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    (2021-11-22T00:00:00Z) Dinc, HARİKA ÖYKÜ; Saltoglu, Nese; Can, Gunay; Balkan, Ilker Inanc; Budak, Beyhan; Ozbey, Dogukan; Caglar, Bilge; Karaali, Rıdvan; Mete, Bilgul; Tuyji Tok, Yesim; Ersoy, Yagmur; Ahmet Kuskucu, Mert; Midilli, Kenan; Ergin, Sevgi; Kocazeybek, Bekir Sami; DİNÇ, HARİKA ÖYKÜ
    Background and objectives: Healthcare workers (HCWs) were among the first groups to be vaccinated in Turkey. The data to be obtained by the vaccination of HCWs would guide wide spread vaccination programs. Materials and methods: The study included 330 HCWs working at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike /RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. Chemiluminescent microparticle immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test (PRNT), was used. Results: Of the participants, 211 (63.9%) were female, 119 (36.1%) were male, and mean age was 39.6 ± 7.7 years. In those without prior COVID-19 history; (n = 255) antibody positivity was detected as 48.2% (95% CI: 42.1-54.3) 14 days after the first dose of vaccine, and 99.2% (95% CI: 98.1-100) at day 28 after the second dose. Antibody titers were significantly lower in patients with hypertension (p = 0.011). In those with prior history of COVID-19 (n = 75); both the antibody positivity rates after the first vaccine (48.2% vs 100%, p = 0.000) and the anti-spike/RBD antibody levels after the second vaccine (with a ≥ 1050 AU/mL titer equivalent to PRNT 1/80 dilution) was significant than infection-naive group (25.9% vs. 54.7%, p = 0.000). Antibody positivity after two doses of vaccination for all study group was 99.4% (95% CI: 98.6-100). Conclusions: Two doses CoronaVac produce effective humoral immunity in HCWs. Antibody response is significantly higher in those with prior history of COVID-19 than infection-naive group. Given no significant benefit of the second dose, a single shot of vaccination may be sufficient for those with prior history of COVID-19. Monitoring humoral and cellular immune responses, considering new variants, is required to validate this approach.
  • Thumbnail Image
    PublicationOpen Access
    Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required
    (2022-03-01T00:00:00Z) BALKAN, İLKER İNANÇ; DİNÇ, HARİKA ÖYKÜ; CAN, GÜNAY; KARAALİ, RIDVAN; Ozbey, Dogukan; ÇAĞLAR, BİLGE; BEYTUR, AYŞE NUR; KESKİN, ELİF; BUDAK, Beyhan; Aydogan, Okan; METE, BİLGÜL; ERGİN, SEVGİ; KOCAZEYBEK, BEKİR SAMİ; SALTOĞLU, NEŞE; DİNÇ, HARİKA ÖYKÜ
    Aims Despite high vaccination rates, increasing case numbers continue to be reported with the identification of new variants of concern, and the issue of durability of the vaccine-induced immune response remains hot topic. Real-life data regarding time-dependent immunogenicity of inactivated COVID-19 vaccines are scarce. We aimed to investigate the changes in the antibody at the different times after the second dose of the CoronaVac vaccine. Methods The study included 175 HCWs vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses. Anti-spike/RBD IgG levels were measured first, third, and sixth months after the second dose. Chemiluminescent microparticle immunoassay (IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test, was used. Results Mean age of the participants was 38 +/- 11.23 years (range between 22 and 66) of whom 119 (63.9%) were female, and 56 (32%) were male. Dramatic reductions were demonstrated in median antibody levels particularly in the infection-naive group, comprising 138 HCWs compared to those with prior history of COVID-19 infection (n = 37) (p < 0.001). There was no difference between the two groups in terms of age, gender, blood groups, BMI, and comorbid diseases. Conclusions While antibody positivity remained above 90% in the 6th month after two doses of inactivated vaccine in HCWs, the median titers of neutralizing antibodies decreased rapidly. The decrease was more rapid and significant in those with no history of prior COVID-19 infection. In this critical phase of the pandemic, where we are facing the dominance of the Omicron variant after Delta, booster doses have become vital.
  • Thumbnail Image
    PublicationOpen Access
    Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.
    (2022-04-05T00:00:00Z) Dinç, HARİKA ÖYKÜ; Demirci, Mehmet; Özdemir, Yusuf Emre; Sirekbasan, Serhat; Aktaş, Ayse Nur; Karaali, Rıdvan; Tuyji Tok, Yeşim; Özbey, Doğukan; Akçin, Rüveyda; Gareayaghi, Nesrin; Kuşkucu, Mert Ahmet; Midilli, Kenan; Aygün, Gökhan; Sarıbaş, Suat; Kocazeybek, Bekir; DİNÇ, HARİKA ÖYKÜ
    Background: Monitoring the longevity of immunoglobulin G (IgG) responses following severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections is vital to understanding the role of antibodies in preventing infection. Aims: To determine the quantitative IgG responses specific to the Spike-S1 (S1) receptor-binding domain (S1/RBD) region of the virus in serum samples taken between 4 weeks and 7 months after polymerase chain reaction (PCR) positivity in patients who are diagnosed with coronavirus disease-2019 (COVID-19). Study design: A longitudinal study. Methods: This study included 113 patients with a clinical and molecular diagnosis of COVID-19. The first and second serum samples were taken 1 and 7 months, respectively, after the PCR positivity. S1/RBD-specific IgG antibody response was assayed using anti-SARS-CoV- 2 QuantiVac ELISA (IgG) kit (Euroimmun, Lübeck, Germany). The neutralizing antibodies were investigated in 57 patients whose IgG test results were above the cut-off value. Results: In 57 patients with SARS-CoV-2 IgG, the anti-SARS-CoV-2 IgG quantitative antibody levels significantly decreased after 7 months (Z = −2.197, p = 0.028). A correlation was detected between the anti-SARS-CoV-2 IgG and nAb percent inhibition (IH%) levels detected in 1 month (rs = 0.496, p < 0.001), but without significant correlation in serum samples taken on 7 months. The nAb IH% levels of the first and second were compared for COVID-19 severity and revealed no statistical difference (p = 0.256). In the second serum sample, the nAb IH%s of patients with moderate COVID-19 showed a statistically significant difference from patients with mild COVID-19 (p = 0.018), but without significant differences between severe and moderate or mild COVID-19. Conclusion: SARS-CoV-2 quantitative IgG antibody titers are significantly reduced at long-term follow-up (> 6 months). Due to the limited information on seroconversion, comprehensive studies should be conducted for long-term follow-up of the immune response against SARS-CoV-2.
  • Thumbnail Image
    PublicationOpen Access
    History of Epidemics and COVID-19
    (2020-12-01T00:00:00Z) YÜKSEL MAYDA, PELİN; DİNÇ, HARİKA ÖYKÜ
    In archaeological excavations, it has been reported that formations resembling bacterial fossils are found among the rock layers and they belong to millions of years ago. There are those who have created the flora and preserved us by creating our flora, and those that have brought us to the end, as well as those that help us to form the microorganisms that we share with the same planet, whose existence dates back to ancient times. Although our immune system and medical facilities are trump cards against microorganisms living in the world for much longer than human beings, these are not always enough to protect us, and microorganisms are causing outbreaks that will make history. In this review, we aimed to examine the epidemic diseases experienced by human beings from past to present and their effects.
  • Thumbnail Image
    PublicationOpen Access
    SARS CoV-2 Pathogenesis and Immune Response
    (2020-12-01T00:00:00Z) Dinç, Harika Öykü; Yüksel Mayda, Pelin; DİNÇ, HARİKA ÖYKÜ; YÜKSEL MAYDA, PELİN
    The agent responsible for the epidemic that first appeared in Wuhan, China, in December 2019 was detected to be the new coronavirus (2019-nCoV). Later, the virus that caused respiratory tract infection was discovered to be a member of the beta-coronavirus family, it was named as severe acute respiratory syndrome-CoV2 (SARS-CoV 2), and the disease it caused was called CoV infection disease-19 (COVID-19). The epidemic started in China, spread rapidly first to East Asian countries, then Europe and America, affected the whole world, and was declared a pandemic by the World Health Organization. This review presents an overview of SARS-CoV2 and aims to examine its intracellular pathogenesis and host immune responses.